Cisplatin + etoposide 2 genotype 63 SNPs in 29 No SNPs were to be associated significant, the 95% CI – patients genes with emesis included 1.0 NQO1 rs1800566 Major outcome(s): Statistical analyses: No report on whether the Association between Nucleotide Genetic models were coded patients were on an candidate gene variants excision repair as additive or dominant antiemetic regimen implicated in CTX drug protein metabolism and CINV Cox proportional hazards Only 80 patients from a occurrence to determine the total of 635 had blood ERCC4 rs744154 association between each sample available for SNP and nausea and genomic analysis vomiting XPC rs2228001 Transcription factor GTF2E1 rs447978 Voltage gated ion channel KCNC1 rs17718902 Motor protein KLC3 rs13181 Integral membrane protein TMEM63A rs10158985 Tumor suppressor TP53 rs1625895
Cisplatin + etoposide – 2 patients Major outcome(s): Association between candidate gene variants implicated in CTX drug metabolism and CINV occurrence NQO1 rs1800566 Nucleotide excision repair protein ERCC4 rs744154 XPC rs2228001 Transcription factor GTF2E1 rs447978 Voltage gated ion channel KCNC1 rs17718902 Motor protein KLC3 rs13181 Integral membrane protein TMEM63A rs10158985 Tumor suppressor TP53 rs1625895 genotype 63 SNPs in 29 genes Statistical analyses: Genetic models were coded as additive or dominant Cox proportional hazards to determine the association between each SNP and nausea and vomiting No SNPs were to be associated with emesis significant, the 95% CI included 1.0 No report on whether the patients were on an antiemetic regimen Only 80 patients from a total of 635 had blood sample available for genomic analysis
1-s2.0-S1040842817302196-mmc1.docx